PRAC recommends new measures to minimise risk of rare but serious liver injury with Esmya for fibroidsThe PRAC has completed its review of Esmya (ulipristal acetate), used to treat moderate to severe symptoms of uterine fibroids (benign tumours of the womb), following reports of serious liver injury.After considering all the evidence, the PRAC concluded that the medicine must not be used in women with liver problems and that certain other patients may start new treatment courses provided they have regular liver tests. In addition, PRACrecommended that Esmya should be used for more than one treatment course only in women who are not eligible for surgery.
